^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Source:
Title:

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Excerpt:
Amino acids 417, 459, and 486 are located at the C-terminal of the kinase domain distant to the imatinib binding site...It is possible that mutation at these sites causes conformational changes to the BCR-ABL protein that alters the equilibrium to the active conformation and impairs imatinib binding...Our data suggest that mutations beyond the activation loop are also implicated in imatinib resistance, and patients with these mutations may benefit from therapeutic intervention.
DOI:
https://doi.org/10.1182/blood-2002-09-2896